Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

Millionaire11 Aug. 20 at 8:26 PM

$CMPS Hey $JNJ we want minimum 5B. Anything less we are turning away.

0 · Reply

SellasgpsCurativeBAT11 Aug. 20 at 7:31 PM

$JNJ $SLS Part 2. JNJ is hunting for a $20B revenue gap to hit $50B in oncology by 2030, pouring cash into AML drugs with POOR durability (4.4 mo post-relapse survival). Meanwhile, $SLS where Big Pharma fails: • SLS009: 8.9 mo MOS (vs 2.5 mo historical) • GPS Curative vs. BAT 11 mOS. Meanwhile, the buyout puzzle pieces click: Leadership Lineup: Tom Cavanagh (leading us $JNJ acquisitions) overlapped directly with Katherine Bach Kalin at Celgene. Inside Bet: Katherine sits on the ras ŞSLS Board and bought 63,400 shares out of pocket (104,400 total). $$$ Muscle: With massive cash flow and pristine balance sheets, $JNJ can easily finance a multibillion dollar buyout. ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Aug. 20 at 7:11 PM

$SLS $JNJ My # 1 Suitor for Sellas $JNJ is looking great. Shifting power dynamics as Big Pharma's H1 2026 revenue rankings are out! The Tier 1 Revenue Leaders • Johnson & Johnson ($49.40B): Retains the #1 spot globally through positioning across innovative medicine and medtech. ✌️🙏❤️‍🩹

0 · Reply

Ryuk Aug. 20 at 6:50 PM

$JNJ And it’s all gone. Puts up +300%.

0 · Reply

Prady Aug. 20 at 6:41 PM

$BSX $JNJ Johnson's buyout price would be north of 80+

1 · Reply

hyenacorp Aug. 20 at 4:27 PM

$JNJ

0 · Reply

JJBurch Aug. 20 at 3:12 PM

$BCTX $TRUG Yep. Told you. LAST CALL ALL ABOARD $JNJ $MRNA $PLTR

1 · Reply

JJBurch Aug. 20 at 2:55 PM

$BCTX 🚨 🚨 UNDER THE RADAR PLAY THAT BENEFITS MOST FROM $MRNA CANCER STUDY!!!!! YOU’RE WELCOME ! Also $TRUG WAY WAY UNDER THE RADAR PLAY THAT IS POISED TO GO 10X IMMINENTLY I GOT YOU!!! CONGRATS AND ENJOY $JNJ $PLTR

2 · Reply

JJBurch Aug. 20 at 2:03 PM

$TRUG MAJOR MOVE IMMINENT. CONFIRMATION! LEVELS SHOW MARKET MAKERS WITH BUYERS MOVING IN SETTING UP EASY TO SEE IN MICRO CAPS HIGHLY UNDERVALUED AND THE BREAKOUT IS NOW HERE. MOMENTS AWAY WATCH IT WATCH IT $MRNA $JNJ $TSLA

0 · Reply

HydrogenH2 Aug. 20 at 1:31 PM

$JNJ Wake me up under $250 !!

1 · Reply

Analysts Back Dividend Aristocrats JNJ and LIN Ahead of Q3 Earnings

LIN

2026-08-17T10:16:04.000Z - 3 days ago

Oppenheimer upgrades Intuitive Surgical on lack of U.S. competition

ISRG

Aug 13, 2026, 11:15 PM EDT - 6 days ago

Expert explains why healthcare is a top-performing sector

ABBV AMGN BIIB GILD LLY MRK UNH

Aug 10, 2026, 4:27 PM EDT - 10 days ago

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

2026-08-07T19:33:43.000Z - 13 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now to Get Paid in September — 8/7/26

CVX WMT

Aug 6, 2026, 6:23 PM EDT - 13 days ago

Jim Cramer highlights 5 investing themes — and the stocks to buy for each

AMAT AXP COF CRWD GS KLAC LLY

2026-08-06T10:48:29.000Z - 14 days ago

Johnson & Johnson price target raised to $287 from $270 at Guggenheim

2026-08-05T18:48:12.000Z - 15 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks for Dependable Income, 8/5/26

IBM KO

Aug 4, 2026, 4:05 PM EDT - 16 days ago

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

2026-08-04T12:50:51.000Z - 16 days ago

Johnson & Johnson announces Taubert to retire as EVP, Worldwide Chairman

Aug 4, 2026, 8:45 AM EDT - 16 days ago

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Aug 3, 2026, 8:00 AM EDT - 17 days ago

Johnson & Johnson Transcript: Investor update

2026-08-03T11:00:29.000Z - 17 days ago

Johnson & Johnson price target raised to $282 from $272 at Wells Fargo

Aug 2, 2026, 8:00 AM EDT - 18 days ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Jul 30, 2026, 8:30 AM EDT - 21 days ago

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Jul 29, 2026, 6:13 PM EDT - 21 days ago

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Jul 29, 2026, 5:42 PM EDT - 21 days ago

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Jul 29, 2026, 5:38 PM EDT - 21 days ago

Johnson & Johnson lowers 2026 profit forecast

Jul 29, 2026, 5:28 PM EDT - 21 days ago

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Jul 29, 2026, 12:01 PM EDT - 22 days ago

Explainer: Can J&J finally put the talc litigation behind it?

Jul 28, 2026, 4:31 PM EDT - 23 days ago

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Jul 28, 2026, 12:26 PM EDT - 23 days ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 1:03 AM EDT - 23 days ago

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

Jul 28, 2026, 12:31 AM EDT - 23 days ago

J&J offers $5.5bn to settle baby powder lawsuits

Jul 27, 2026, 9:29 PM EDT - 23 days ago

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Jul 27, 2026, 6:47 PM EDT - 23 days ago

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Jul 27, 2026, 6:31 PM EDT - 23 days ago

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Jul 27, 2026, 5:45 AM EDT - 24 days ago

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

NEM WMT

$TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma$

Jul 23, 2026, 8:30 AM EDT - 4 weeks ago

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 22, 2026, 4:33 PM EDT - 4 weeks ago

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Jul 22, 2026, 7:21 AM EDT - 4 weeks ago

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Jul 22, 2026, 7:00 AM EDT - 4 weeks ago

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jul 21, 2026, 6:30 PM EDT - 4 weeks ago

Jim Cramer says this old-school investing concept still wins — even in the AI boom

BNY CVS GS MMM WFC

Jul 16, 2026, 8:11 AM EDT - 5 weeks ago

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Jul 16, 2026, 8:00 AM EDT - 5 weeks ago

DePuy Synthes Acquires Expanding Innovations™

Jul 15, 2026, 12:09 PM EDT - 5 weeks ago

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 7:27 AM EDT - 5 weeks ago

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

ASML INTC

Jul 15, 2026, 6:35 AM EDT - 5 weeks ago

Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:33 AM EDT - 5 weeks ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:25 AM EDT - 5 weeks ago

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Jul 15, 2026, 6:23 AM EDT - 5 weeks ago

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Jul 15, 2026, 6:20 AM EDT - 5 weeks ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 9, 2026, 1:00 PM EDT - 6 weeks ago

The Big 3: UNH, KO, JNJ

KO UNH

Jul 8, 2026, 7:45 AM EDT - 6 weeks ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 6, 2026, 6:29 PM EDT - 6 weeks ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Jun 26, 2026, 2:39 PM EDT - 7 weeks ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Jun 26, 2026, 12:35 PM EDT - 7 weeks ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 25, 2026, 5:00 AM EDT - 2 months ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 15, 2026, 6:00 AM EDT - 2 months ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

$New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:41 AM EDT - 2 months ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:33 AM EDT - 2 months ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 11, 2026, 7:45 AM EDT - 2 months ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 2:03 AM EDT - 2 months ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 10, 2026, 11:22 AM EDT - 2 months ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 6:20 AM EDT - 2 months ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 9, 2026, 10:00 AM EDT - 2 months ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Jun 8, 2026, 9:01 AM EDT - 2 months ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Millionaire11 Aug. 20 at 8:26 PM

$CMPS Hey $JNJ we want minimum 5B. Anything less we are turning away.

0 · Reply

SellasgpsCurativeBAT11 Aug. 20 at 7:31 PM

0 · Reply

SellasgpsCurativeBAT11 Aug. 20 at 7:11 PM

0 · Reply

Ryuk Aug. 20 at 6:50 PM

$JNJ And it’s all gone. Puts up +300%.

0 · Reply

Prady Aug. 20 at 6:41 PM

$BSX $JNJ Johnson's buyout price would be north of 80+

1 · Reply

hyenacorp Aug. 20 at 4:27 PM

$JNJ

0 · Reply

JJBurch Aug. 20 at 3:12 PM

$BCTX $TRUG Yep. Told you. LAST CALL ALL ABOARD $JNJ $MRNA $PLTR

1 · Reply

JJBurch Aug. 20 at 2:55 PM

2 · Reply

JJBurch Aug. 20 at 2:03 PM

0 · Reply

HydrogenH2 Aug. 20 at 1:31 PM

$JNJ Wake me up under $250 !!

1 · Reply

SellasgpsCurativeBAT11 Aug. 20 at 12:30 PM

$SLS $BMY $JNJ $BMY and $JNJ have been my Top 2 suitors for $SLS $BMY Billion Dollar Blockbuster Ventoclax will become Obsolete after GPS Approval. $BMY makes a move for Sellas GPS can not only protect Ventoclax but Maintenance Combo in 20+ WT1 cancers can Top Merck’s Keytruda Revenues of $31 Billion Annually. $JNJ is already on the table courting Sellas. Sellas Executive team quiet period on all clinical and corporate front points to an outright BO deal in works. Stay Tuned things will move quickly here. Moderna data yesterday is about to awake the cancer KRAKEN. ✌️🙏❤️‍🩹

0 · Reply

ForwardCurveCapital Aug. 20 at 12:05 PM

$JNJ 📊 GlobalUSAEuity ▲ 273.41 (+0.85%) Trend: Strong Uptrend 🚀 RSI (14): 79.15 (Overbought ⚠️) MACD: Bullish, above signal line and rising 🟢 Volume: Normal ➖ 📌 Key Levels Resistance: 276.47 Support: 250.44 20-MA: 261.4 | 50-MA: 253.59 Educational content only. Not financial advice.

0 · Reply

JuggernautRaider Aug. 20 at 11:37 AM

$BMY looking strong as a NJ pharma bond $PFE $NVS $JNJ too!!! 💫

0 · Reply

Flatflounder7 Aug. 20 at 11:28 AM

$AI $DGXX $EOSE $JNJ Digi ain’t spec, that mf is delivering

1 · Reply

aaa1233 Aug. 20 at 11:23 AM

When a company the size of $JNJ publicly states AML still needs longer-lasting remissions, more effective options after relapse, subtype-specific treatments, and better tolerated approaches for older patients, it reinforces how much unmet need remains in AML. Those are the exact problems GPS and SLS009 are being developed to address. $SLS https://www.jnj.com/health-and-wellness/what-is-acute-myeloid-leukemia

1 · Reply

StockBraker Aug. 20 at 11:21 AM

$JNJ https://www.investor.jnj.com/pipeline/development-pipeline/default.aspx

0 · Reply

Imr77 Aug. 20 at 11:01 AM

$SLS well $MRK seems like $JNJ stole the trump card

0 · Reply

TeresaLey863 Aug. 20 at 7:27 AM

$V $JNJ $MA $INTC $ABBV Visa and Mastercard benefit from electronic-payment growth, Johnson & Johnson provides diversified healthcare exposure, Intel remains focused on semiconductor manufacturing and AI opportunities, and AbbVie benefits from its pharmaceutical portfolio. I'm watching payment volumes, healthcare demand, foundry execution, and prescription growth.

0 · Reply

KathiDavis693 Aug. 20 at 7:06 AM

$DGXX $AI $EOSE $JNJ DGXX remains highly speculative, C3.ai remains focused on enterprise AI adoption, Eos Energy advances long-duration battery storage, and Johnson & Johnson provides diversified healthcare exposure. I'm watching funding, AI contracts, storage deployments, clinical catalysts, and healthcare demand.

0 · Reply

SniperAlphaCom Aug. 20 at 2:45 AM

$JNJ TS Update #3. Another higher high, another adjustment to the trailing stop. The position remains active and the stop now moves up with the structure — not the noise. From breakout → TS #1 → TS #2 → TS #3. Let the trend work until price says otherwise.

0 · Reply

Secretweapon Aug. 19 at 11:28 PM

$JNJ buying moderna? BUYOUT

0 · Reply

Orchard Aug. 19 at 11:16 PM

$JNJ $MRNA $LLY $PFE So JNJ couldn’t make sunscreen that didn’t cause cancer, and we now have a “cure for cancer” made with the same tech that caused my friend to go blind in his right eye from a $MRNA spike protein gene therapy with no long term testing…

0 · Reply

Market Cap	653.35B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	24.16
Forward PE	22.60
Profit Margin	28.46%
Debt to Equity Ratio	0.44

Volume	6,451,332
Avg Vol	8,162,900
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	86%
Beta	0.24
Analysts	Strong Sell
Price Target	$275.42